Last reviewed · How we verify
Ibuprofen 250 mg
At a glance
| Generic name | Ibuprofen 250 mg |
|---|---|
| Also known as | IBU 250 |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ERAS (Enhanced Recovery After Surgery) and Multimodal Analgesia in Laparoscopic Cholecystectomy
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing (PHASE2)
- Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial (PHASE4)
- A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects (PHASE1)
- Assessment of Different Clinical Techniques to Treat Patients With Chronic Low Back Pain (NA)
- Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder (PHASE2, PHASE3)
- Efficacy of Intravenous Ibuprofen and Paracetamol on Postoperative Pain and Tramadol Consumption in Shoulder Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibuprofen 250 mg CI brief — competitive landscape report
- Ibuprofen 250 mg updates RSS · CI watch RSS
- Pfizer portfolio CI